AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21994078 — intervention group
Group type: COMPARATOR
Intervention: Three-port laparoscopic procedure
Number of subjects: 13
Study 19056034 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored no longer than 7 days
Number of subjects: 450
Study 19056034 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (RBCs stored longer than 7 days)
Number of subjects: 450
Study 19056034 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 450
Study 17995495 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG‐IUS)
Number of subjects: 113
Study 17995495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LNG‐IUS)
Number of subjects: 113
Study 16699904 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 1651
Study 16699904 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/wk
Number of subjects: 1651
Study 16699904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651
Study 16699904 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 1651
Study 11752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 23
Study 11752040 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 23
Study 11752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tacrolimus and cyclosporine
Number of subjects: 23
Study 11752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine
Number of subjects: 23
Study 9883710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of valsartan (80 mg or 160 mg) and HCTZ (12.5 mg or 25 mg)
Number of subjects: 871
Study 9883710 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg or 160 mg) alone
Number of subjects: 871
Study 9883710 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ (12.5 mg or 25 mg) alone
Number of subjects: 871
Study 9883710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 7976233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 100 mg three times daily
Number of subjects: 76
Study 7976233 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg three times daily
Number of subjects: 76
Study 2968266 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta‐oestradiol combined with progesterone (n = 29)
Number of subjects: 191
Study 2968266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol valerate combined with cyproterone acetate (n = 37)
Number of subjects: 191
Study 2968266 — intervention group
Group type: EXPERIMENTAL
Intervention: 24R, 25 (OH)2D3 (n = 29)
Number of subjects: 191
Study 2968266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 191
Study 2968266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 191
Study 2968266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 191
Study 31789303 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing based on feedforward control
Number of subjects: 114
Study 31789303 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 114
Study 28372315 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy back squat (90-95% of one repetition maximum)
Number of subjects: 22
Study 28372315 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity back squat (60-65% of one repetition maximum)
Number of subjects: 22
Study 25811573 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheets for 2 months
Number of subjects: 36
Study 25811573 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheets for 6 months
Number of subjects: 36
Study 25811573 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 36
Study 22672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) derived Myocardial Performance Index of Right Ventricle (MPI-RV)
Number of subjects: 41
Study 22672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 41
Study 22672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension detection
Number of subjects: 41
Study 22672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of MPI-RV with pulmonary artery pressures and left ventricular ejection fraction
Number of subjects: 41
Study 22672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MPI-RV in ESRD patients with and without pulmonary hypertension
Number of subjects: 41
Study 20441516 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 0
Study 20441516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18807678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (Proplex T)
Number of subjects: 0
Study 18807678 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin K and fresh-frozen plasma)
Number of subjects: 0
Study 16191080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis
Number of subjects: 35
Study 16191080 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysis
Number of subjects: 35
Study 12011552 — intervention group
Group type: EXPERIMENTAL
Intervention: Short (3-day) hospitalization followed by home care treatment
Number of subjects: 102
Study 12011552 — intervention group
Group type: COMPARATOR
Intervention: Conventional (10-day) hospitalization
Number of subjects: 102
Study 10380161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ppm NO2
Number of subjects: 8
Study 10380161 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 8
Study 7776711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) at stepped doses increasing to 20 mg four times daily for 4 days
Number of subjects: 34
Study 7776711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2185967 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (25 micrograms/h)
Number of subjects: 56
Study 2185967 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (25 micrograms/h for 48 h)
Number of subjects: 56
Study 2185967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2185967 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal tamponade
Number of subjects: 56
Study 6786091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (4-4.5 kg./6.5 cm.2 x 2 min.)
Number of subjects: 18
Study 6786091 — intervention group
Group type: COMPARATOR
Intervention: Bouginage (44-55 ff catheter)
Number of subjects: 18
Study 31519347 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Patients (SPs) usage
Number of subjects: 0
Study 31519347 — intervention group
Group type: COMPARATOR
Intervention: Control group (theoretical lecture)
Number of subjects: 0
Study 28624914 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus desiccant (Hybenx®)
Number of subjects: 36
Study 26786905 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Based Cognitive‐Behavioral Social Work (FBCBSW) intervention
Number of subjects: 27
Study 26786905 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 25157535 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI sessions (2 sessions, each lasting 1.5 hours)
Number of subjects: 9
Study 23063168 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin for 6 weeks
Number of subjects: 80
Study 23063168 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study 20139236 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfection by-products (DBPs) exposure in drinking water
Number of subjects: 13
Study 18344439 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 826
Study 18344439 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 826
Study 18344439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with target-vessel ischemia
Number of subjects: 826
Study 18344439 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-vessel ischemia
Number of subjects: 826
Study 15800310 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur)
Number of subjects: 2934
Study 15800310 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM (tamoxifen)
Number of subjects: 2934
Study 15800310 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 2934
Study 12452224 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 120
Study 12452224 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 120
Study 12452224 — intervention group
Group type: COMPARATOR
Intervention: Age group (≥60 years)
Number of subjects: 120
Study 12452224 — intervention group
Group type: COMPARATOR
Intervention: Age group (<60 years)
Number of subjects: 120
Study 10506720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen inhalation alone
Number of subjects: 61
Study 10506720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen inhalation with oral nicotinamide (80 mg/kg)
Number of subjects: 61
Study 7554702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 to 80 mg) taken with water in the fasting state
Number of subjects: 1
Study 7554702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate taken 60 or 30 minutes before a standardized breakfast
Number of subjects: 1
Study 7554702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate taken concurrently with or 2 hours after breakfast
Number of subjects: 1
Study 7554702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate taken with black coffee or orange juice
Number of subjects: 1
Study 7554702 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate with ranitidine infusion to increase gastric pH
Number of subjects: 1
Study 2249704 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version of the prereferral intervention (n = 24)
Number of subjects: 60
Study 2249704 — intervention group
Group type: EXPERIMENTAL
Intervention: Long version of the prereferral intervention (n = 24)
Number of subjects: 60
Study 2249704 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 60
Study 6786094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 6786094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31477085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric low glycemic index (LGI) diet for 24 weeks
Number of subjects: 62
Study 28291178 — intervention group
Group type: EXPERIMENTAL
Intervention: HYA‐JOINT Plus (3 mL, 20 mg/mL)
Number of subjects: 132
Study 28291178 — intervention group
Group type: COMPARATOR
Intervention: Synvisc‐One (6 mL, 8 mg/mL)
Number of subjects: 132
Study 25644634 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation splint treatment with counselling and masticatory muscle exercises
Number of subjects: 80
Study 25644634 — intervention group
Group type: COMPARATOR
Intervention: Counselling and masticatory muscle exercises (Control)
Number of subjects: 80
Study 24252703 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted vaccine (3.75 μg hemagglutinin)
Number of subjects: 310
Study 24252703 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03B-adjuvanted vaccine (1.9 μg hemagglutinin, one or two doses)
Number of subjects: 310
Study 24252703 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted 15 μg HA pandemic vaccine
Number of subjects: 310
Study 24252703 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 310
Study 24252703 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines
Number of subjects: 310
Study 24252703 — intervention group
Group type: EXPERIMENTAL
Intervention: All study vaccines
Number of subjects: 310
Study 21184272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day (n=21)
Number of subjects: 57
Study 21184272 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (n=16)
Number of subjects: 57
Study 21184272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 57
Study 19864101 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural-enhancement (SE) function used during video colonoscopy
Number of subjects: 593
Study 19864101 — intervention group
Group type: COMPARATOR
Intervention: Standard video colonoscopy without SE function
Number of subjects: 593
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 500 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 750 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1000 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1250 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate 1500 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 500 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 750 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 1000 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine phosphate (multiple doses) 1500 mg
Number of subjects: 0
Study 18199893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15630030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010
Study 11969278 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 416
Study 11969278 — intervention group
Group type: COMPARATOR
Intervention: Pre-dilated stenting
Number of subjects: 416
Study 10587839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion (4.35 mmol.kg‐1.h‐1)
Number of subjects: 10
Study 10587839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 10
Study 8539159 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI (reference pacing mode)
Number of subjects: 20
Study 8539159 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/AMC (automatic mode conversion)
Number of subjects: 20
Study 8539159 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/AMC+acc
Number of subjects: 20
Study 8539159 — intervention group
Group type: COMPARATOR
Intervention: OOO (CSM without pacing)
Number of subjects: 20
Study 2294326 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation by a geriatric assessment team
Number of subjects: 600
Study 2294326 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation by a 'second opinion' internist
Number of subjects: 600
Study 2294326 — intervention group
Group type: COMPARATOR
Intervention: Traditional health maintenance organization services
Number of subjects: 600
Study 307732 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol
Number of subjects: 2
Study 307732 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2
Number of subjects: 2
Study 31769181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led self-management program
Number of subjects: 154
Study 30019283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic biopsy
Number of subjects: 80
Study 30019283 — intervention group
Group type: COMPARATOR
Intervention: Conventional excisional biopsy
Number of subjects: 80
Study 27980221 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil and Tegafur (UFT) maintenance therapy (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity
Number of subjects: 58
Study 27980221 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 58
Study 25916084 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ-100)
Number of subjects: 45
Study 25916084 — intervention group
Group type: COMPARATOR
Intervention: Control (no TJ-100)
Number of subjects: 45
Study 23955492 — intervention group
Group type: EXPERIMENTAL
Intervention: Women distressed about low sexual desire
Number of subjects: 2
Study 23955492 — intervention group
Group type: COMPARATOR
Intervention: Women not distressed about low sexual desire
Number of subjects: 2
Study 21404147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam sublingual tablets (ALP-SL)
Number of subjects: 190
Study 21404147 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam conventional tablets (ALP-CT)
Number of subjects: 190
Study 18353468 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent implantation, N=25
Number of subjects: 117
Study 18353468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordis coil stent implantation, N=24
Number of subjects: 117
Study 18353468 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty, N=42 (23 + 19)
Number of subjects: 117
Study 17303799 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin (50 mg b.i.d.)
Number of subjects: 14
Study 17303799 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 14648339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose enalapril (0.2 mg/kg daily)
Number of subjects: 25
Study 14648339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose enalapril (0.6 mg/kg daily)
Number of subjects: 25
Study 14648339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose enalapril
Number of subjects: 25
Study 14648339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-dose enalapril
Number of subjects: 25
Study 14648339 — intervention group
Group type: EXPERIMENTAL
Intervention: End of 20 weeks treatment
Number of subjects: 25
Study 14648339 — intervention group
Group type: COMPARATOR
Intervention: Systolic and diastolic blood pressure
Number of subjects: 25
Study 11409580 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin 5 mg/kg
Number of subjects: 59
Study 11409580 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin 10 mg/kg
Number of subjects: 59
Study 11409580 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin 15 mg/kg
Number of subjects: 59
Study 11409580 — intervention group
Group type: EXPERIMENTAL
Intervention: isoniazid 6 mg/kg
Number of subjects: 59
Study 11409580 — intervention group
Group type: COMPARATOR
Intervention: no drug
Number of subjects: 59
Study 9744148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice with cholesterol measurement
Number of subjects: 635
Study 9744148 — intervention group
Group type: COMPARATOR
Intervention: No dietary advice but cholesterol measurement
Number of subjects: 635
Study 9744148 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 635
Study 9744148 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 635
Study 9744148 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 635
Study 7828565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (mean: 5.4 ml)
Number of subjects: 79
Study 7828565 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (mean: 12.1 ml)
Number of subjects: 79
Study 3237047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 9
Study 3237047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 g NaHCO3·kg‐1 body weight (B)
Number of subjects: 9
Study 3237047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 g NaHCO3·kg‐1 body weight (C)
Number of subjects: 9
Study 3237047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 g NaHCO3·kg‐1 body weight (D)
Number of subjects: 9
Study 31194877 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220
Study 31194877 — intervention group
Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 220
Study 29379001 — intervention group
Group type: COMPARATOR
Intervention: Single Bond Universal (SBU) - uncontaminated (control)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-1 (cont-1)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-2 (cont-2)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-3 (cont-3)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-4 (cont-4)
Number of subjects: 75
Study 29379001 — intervention group
Group type: COMPARATOR
Intervention: All-Bond Universal (ABU) - uncontaminated (control)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-1 (cont-1)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-2 (cont-2)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-3 (cont-3)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-4 (cont-4)
Number of subjects: 75
Study 29379001 — intervention group
Group type: COMPARATOR
Intervention: Clearfil S3 Bond Plus (CSBP) - uncontaminated (control)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-1 (cont-1)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-2 (cont-2)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-3 (cont-3)
Number of subjects: 75
Study 29379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-4 (cont-4)
Number of subjects: 75